Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCDANASDAQ:CSCINASDAQ:HOTHNYSE:IBIO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCDABioCardia$2.08-1.9%$2.25$1.63▼$4.66$10.77M0.82262,582 shs37,800 shsCSCICOSCIENS Biopharma$3.40-2.6%$3.45$1.96▼$6.77$10.38M0.7411,649 shs1,751 shsHOTHHoth Therapeutics$1.21-9.7%$0.98$0.58▼$3.80$15.98M0.553.71 million shs966,126 shsIBIOiBio$0.77-14.3%$0.88$0.64▼$6.89$12.74M0.96448,033 shs926,644 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCDABioCardia0.00%-4.59%+9.47%-21.80%-41.24%CSCICOSCIENS Biopharma0.00%-4.79%-4.15%+3.31%+339,899,900.00%HOTHHoth Therapeutics0.00%-6.92%+44.12%+12.04%+32.97%IBIOiBio0.00%-16.93%-2.77%-83.35%-66.18%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBCDABioCardia3.5295 of 5 stars3.85.00.00.02.22.50.6CSCICOSCIENS BiopharmaN/AN/AN/AN/AN/AN/AN/AN/AHOTHHoth Therapeutics3.2163 of 5 stars3.65.00.00.02.90.80.6IBIOiBio1.5684 of 5 stars3.50.00.00.01.80.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCDABioCardia 3.50Strong Buy$25.001,101.92% UpsideCSCICOSCIENS Biopharma 0.00N/AN/AN/AHOTHHoth Therapeutics 3.25Buy$4.00230.58% UpsideIBIOiBio 3.00Buy$4.30457.72% UpsideCurrent Analyst Ratings BreakdownLatest IBIO, HOTH, CSCI, and BCDA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/12/2025HOTHHoth TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.005/5/2025IBIOiBioChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.004/15/2025HOTHHoth TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.003/31/2025HOTHHoth TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.00(Data available from 6/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCDABioCardia$60K179.57N/AN/A$0.18 per share11.56CSCICOSCIENS Biopharma$9.59M1.12N/AN/A$3.49 per share0.97HOTHHoth TherapeuticsN/AN/AN/AN/A$0.86 per shareN/AIBIOiBio$375K33.96N/AN/A$1.41 per share0.55Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCDABioCardia-$7.95M-$2.33N/AN/AN/AN/A-30,792.60%-223.06%8/12/2025 (Estimated)CSCICOSCIENS Biopharma-$15.31M-$5.80N/A∞N/A-194.50%-101.01%-43.90%8/12/2025 (Estimated)HOTHHoth Therapeutics-$8.19M-$1.14N/AN/AN/AN/A-109.18%-100.22%8/8/2025 (Estimated)IBIOiBio-$24.91MN/A0.00N/AN/AN/A-73.15%-45.51%N/ALatest IBIO, HOTH, CSCI, and BCDA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025BCDABioCardia-$0.39-$0.59-$0.20-$0.59N/AN/A5/13/2025Q1 2025CSCICOSCIENS BiopharmaN/A-$1.16N/A-$1.16N/A$1.50 million5/12/2025Q1 2025HOTHHoth Therapeutics-$0.34-$0.27+$0.07-$0.27N/AN/A4/9/2025Q4 2024CSCICOSCIENS Biopharma-$3.48-$2.15+$1.33-$2.15$1.10 million$3.32 million3/27/2025Q4 2024HOTHHoth Therapeutics-$0.39-$0.32+$0.07-$0.32N/AN/A3/26/2025Q4 2024BCDABioCardia-$0.87-$0.25+$0.62-$0.25$0.02 million$0.02 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCDABioCardiaN/AN/AN/AN/AN/ACSCICOSCIENS BiopharmaN/AN/AN/AN/AN/AHOTHHoth TherapeuticsN/AN/AN/AN/AN/AIBIOiBioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCDABioCardiaN/A0.360.36CSCICOSCIENS BiopharmaN/A2.882.54HOTHHoth TherapeuticsN/A15.0915.08IBIOiBio0.051.761.76Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCDABioCardia20.57%CSCICOSCIENS Biopharma0.73%HOTHHoth Therapeutics7.08%IBIOiBio7.90%Insider OwnershipCompanyInsider OwnershipBCDABioCardia20.00%CSCICOSCIENS Biopharma0.10%HOTHHoth Therapeutics10.56%IBIOiBio0.58%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCDABioCardia405.18 million4.14 millionOptionableCSCICOSCIENS Biopharma203.15 million3.14 millionN/AHOTHHoth Therapeutics413.21 million11.81 millionNot OptionableIBIOiBio10016.52 million9.82 millionN/AIBIO, HOTH, CSCI, and BCDA HeadlinesRecent News About These CompaniesiBio (NYSE:IBIO) Trading Up 10.5% - Still a Buy?June 19 at 2:37 AM | americanbankingnews.comiBio Extends Promissory Note Maturity to 2026June 18, 2025 | tipranks.comIbio nominates IBIO-610 as obesity development candidateJune 18, 2025 | bioworld.comiBio Initiates Non-Human Primate Study of First-in-Class Activin E Antibody Following Positive Preclinical Data Demonstrating Prevention in Weight Regain After GLP-1 TreatmentJune 16, 2025 | globenewswire.comMinister hails ‘exciting’ degree where students spend two years working in industryMay 29, 2025 | irishtimes.comiBio’s First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical ModelMay 5, 2025 | finance.yahoo.comiBio's First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical ModelMay 5, 2025 | globenewswire.comiBio, Inc. Reports Strong Q3 2025 ProgressMay 5, 2025 | tipranks.comiBio Reports Fiscal Third Quarter 2025 Financial ResultsMay 2, 2025 | globenewswire.comiBio, Inc.: iBio Raises $6.2 Million Through Warrant Inducement TransactionMay 1, 2025 | finanznachrichten.deiBio, Inc. Announces Agreement to Exercise Existing Warrants for $6.2 Million in Gross ProceedsApril 29, 2025 | quiverquant.comiBio Raises $6.2 Million Through Warrant Inducement TransactionApril 29, 2025 | globenewswire.comiBio Enters Licensing Agreement for Obesity TreatmentApril 22, 2025 | tipranks.comiBio, Inc. Enters Licensing Agreement with AstralBio for First-in-Class Activin E-Targeting Antibody to Address Obesity and Cardiometabolic DiseasesApril 22, 2025 | quiverquant.comiBio Expands Cardiometabolic and Obesity Pipeline through Licensing of First-in-Class Antibody Targeting Activin E from AstralBioApril 22, 2025 | globenewswire.comIbio reports preclinical results for antibodies in cardiometabolic and obesity pipelineApril 8, 2025 | bioworld.comiBio Stock Plummets Despite Positive Data On Weight-Loss Treatment Antibody: Retail Stays BearishApril 8, 2025 | msn.comiBio Highlights Advancements in Obesity Antibody ProgramsApril 8, 2025 | tipranks.comiBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity PipelineApril 7, 2025 | globenewswire.comiBio, Inc. Advances in Therapeutics and LeadershipFebruary 21, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIBIO, HOTH, CSCI, and BCDA Company DescriptionsBioCardia NASDAQ:BCDA$2.08 -0.04 (-1.89%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$2.21 +0.13 (+6.25%) As of 06/20/2025 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.COSCIENS Biopharma NASDAQ:CSCI$3.40 -0.09 (-2.61%) Closing price 06/20/2025 03:57 PM EasternExtended Trading$3.40 +0.00 (+0.03%) As of 06/20/2025 07:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.COSCIENS Biopharma Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism. The company was formerly known as Aeterna Zentaris Inc. and changed its name to COSCIENS Biopharma Inc. in August 2024. COSCIENS Biopharma Inc. was incorporated in 1990 and is headquartered in Toronto, Canada.Hoth Therapeutics NASDAQ:HOTH$1.21 -0.13 (-9.70%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$1.20 -0.01 (-1.24%) As of 06/20/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus, as well as a diagnostic device through a mobile device. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; Virginia Commonwealth University; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.iBio NYSE:IBIO$0.77 -0.13 (-14.33%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$0.78 +0.01 (+1.82%) As of 06/20/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.iBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers; MUC16, a tumor-associated epitope; anti-EGFRvIII antibody to treat glioblastoma and other cancers; CCR8 protein candidate for treatment of various cancers; PD-1 agonist for the treatment of rheumatoid arthritis and other inflammatory diseases; and IBIO-400 for the treatment of classical swine fever. iBio, Inc. has agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; and a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Smith & Wesson Stock Falls on Earnings Miss, Tariff Woes Marvell's New AI Chip Deals Capture Wall Street’s Attention Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer GE Aerospace Turns Engines Into Long-Term Profits 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
